1. Home
  2. PRTA

as of 11-20-2026 1:51pm EST

$8.15
$0.25
-2.98%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Founded: 2012 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 2
Market Cap: 429.2M IPO Year: 2013
Target Price: $21.40 AVG Volume (30 days): 420.1K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.05 EPS Growth: -99.56
52 Week Low/High: $7.70 - $11.80 Next Earning Date: 11-05-2026
Revenue: $814,000 Revenue Growth: -14.76%
Revenue Growth (this year): 775.41% Revenue Growth (next year): -71.05%
P/E Ratio: -168.00 Index:
Free Cash Flow: N/A FCF Growth: N/A

Stock Insider Trading Activity of Prothena Corporation plc (PRTA)

Buy
PRTA Nov 9, 2026

Avg Cost/Share

$8.53

Shares

140,000

Total Value

$1,194,158.00

Owned After

977,000

SEC Form 4

Buy
PRTA Oct 23, 2026

Avg Cost/Share

$8.07

Shares

50,000

Total Value

$403,525.00

Owned After

977,000

SEC Form 4

Buy
PRTA Oct 22, 2026

Avg Cost/Share

$8.19

Shares

100,000

Total Value

$818,520.00

Owned After

977,000

SEC Form 4

Buy
PRTA Oct 14, 2026

Avg Cost/Share

$8.46

Shares

10,000

Total Value

$84,569.00

Owned After

977,000

SEC Form 4

Buy
PRTA Oct 13, 2026

Avg Cost/Share

$8.35

Shares

100,000

Total Value

$835,480.00

Owned After

977,000

SEC Form 4

Buy
PRTA Oct 8, 2026

Avg Cost/Share

$8.57

Shares

90,000

Total Value

$770,904.00

Owned After

977,000

SEC Form 4

Buy
PRTA Oct 7, 2026

Avg Cost/Share

$8.40

Shares

125,000

Total Value

$1,050,150.00

Owned After

977,000

SEC Form 4

Buy
PRTA Oct 2, 2026

Avg Cost/Share

$8.57

Shares

100,000

Total Value

$857,240.00

Owned After

977,000

SEC Form 4

Buy
PRTA Sep 29, 2026

Avg Cost/Share

$8.68

Shares

162,000

Total Value

$1,405,674.00

Owned After

977,000

SEC Form 4

Buy
PRTA Sep 18, 2026

Avg Cost/Share

$8.43

Shares

100,000

Total Value

$843,460.00

Owned After

977,000

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 5, 2026 · 100% conf.

AI Prediction BUY

1D

+5.30%

$8.83

Act: +1.14%

5D

+6.24%

$8.91

20D

+7.58%

$9.03

Price: $8.39 Prob +5D: 100% AUC: 1.000
0001559053-26-000030

EX-99.1

2 exhibit991q32026earningsre.htm

EX-99.1

Document

Exhibit 99.1

PRESS RELEASE

Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

•Net cash used in operating and investing activities was $12.0 million in the third quarter and net cash used in operating and investing activities was $8.9 million for the first nine months of 2026; quarter-end cash and restricted cash position was $272.2 million

•Novo recently presented post hoc analyses at the Heart Failure Society of America (HFSA) Annual Scientific Meeting from the coramitug Phase 2 trial which demonstrated a decrease of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) in patients treated with coramitug as compared to an increase in patients on placebo, further supporting the potential of coramitug as a treatment for ATTR-CM

•Multiple research collaborations with industry partners ongoing to explore the potential of our CYTOPE® technology over the next 12 to 24 months

DUBLIN, Ireland, November 5, 2026 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2026 and provided business highlights.

“During the quarter, Roche and Novo highlighted prasinezumab at Roche’s Pharma Day and coramitug at Novo’s Capital Markets Day, underscoring the potential of these Prothena-originated programs to address significant unmet needs in Parkinson’s disease and ATTR amyloidosis with cardiomyopathy, respectively. Novo also recently presented a post hoc analysis of the Phase 2 trial at the HFSA Annual Scientific Meeting showing that the inflammatory biomarker hsCRP decreased from baseline in patients treated with coramitug, while increasing in those receiving placebo. These findings complement the previously reported reduction in NT-proBNP and favorable functional and echocardiographic findings, further supporting coramitug’s potential as an amyloid-depleting treatment for ATTR-CM. Both programs are in Phase 3 clinical trials, PARAISO (prasinezumab) and CLEOPATTRA (coramitug), with primary completions expected in 2029,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. “Bristol Myers Squibb continues to conduct the Phase 2 TargetTau-1 trial evaluating moponetug in patients with early Alzheimer’s disease, with data readout expected in the first half of 2027. Through our partnered programs, we have generated $650 million in upfront, milestone and equity payments and may potentially receive over $2.25 billion in additional milestone payments, plus potential royalties. Additionally, we are progressing our wholly-owned preclinical programs, including PRX012-TfR and TDP-43 CYTOPE. And finally, we continue to evaluate our proprietary CYTOPE® technology with industry partners through multiple research collaborations over the next 12 to 24 months.”

Business Highlights and Upcoming Milestones

Clinical Development Portfolio

Prasinezumab, a potential first-in-class antibody for the treatment of Parkinson’s disease that is designed to target a key epitope within the C-terminus of alpha-synuclein and is the focus of a worldwide collaboration with Roche.

•Roche is conducting the Phase 3 PARAISO clinical trial in approximately 900 participants for a minimum of 104 weeks with early-stage Parkinson's disease on stable symptomatic monotherapy with levodopa; primary completion expected in 2029 (NCT07174310)

•Roche has stated that prasinezumab has peak sales potential greater than $3.5 billion (unadjusted) and could be the first disease-modifying treatment for Parkinson’s disease—a condition that affects 10 million people worldwide

Coramitug (formerly PRX004), a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) designed to deplete the pathogenic, non-native forms of the transthyretin (TTR) protein, is being developed by Novo as part of its up to $1.2 billion acquisition of Prothena’s ATTR amyloidosis business and pipeline.

•Novo is conducting the Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)

•Novo recently presented post hoc analyses of its Phase 2 coramitug trial at the HFSA Annual Scientific Meeting. At week 52, the pooled coramitug dose groups (10 and 60 mg/kg) reported an ~8% decrease of the inflammatory biomarker hsCRP, compared with an ~33% increase with placebo (treatment ratio versus placebo: 0.66; nominal p=0.0269)

•Open-label study ongoing to evaluate the biodistribution of 89Zr-coramitug and investigate the effects of coramitug on depleting TTR amyloid deposits in myocardial tissues using PET/CT imaging in participants with ATTR-CM; primary completion expected in 2027 (NCT07448623)

•Coramitug granted Fast Track designation from th

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 6, 2026 · 100% conf.

AI Prediction SELL

1D

+0.61%

$8.63

Act: +2.10%

5D

-5.69%

$8.09

20D

-15.04%

$7.29

Price: $8.58 Prob +5D: 0% AUC: 1.000
0001559053-26-000021

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786368333.caccebb7

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

+0.45%

$10.58

Act: +2.18%

5D

-5.63%

$9.94

Act: -6.36%

20D

-14.89%

$8.96

Act: -16.52%

Price: $10.53 Prob +5D: 0% AUC: 1.000
0001559053-26-000016

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784333969.ccc81e22

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: